Author

Edmund V Ekoka Omoruyi

Observed names: E.V. Ekoka Omoruyi, Edmund Omoruyi

Observed institutions: Janssen (Belgium), Galapagos (Belgium)

ORCID: 0009-0006-5893-3630

Observed ORCID: 0009-0006-5893-3630

OpenAlex ID: A5017909182

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

2020 · Kristi Williams, Arangassery Rosemary Bastian, et al. · The Journal of Infectious Diseases · 110

Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults

2020 · Jerald Sadoff, Els De Paepe, et al. · The Journal of Infectious Diseases · 55

PDF

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

2022 · Arabella S V Stuart, Miia Virta, et al. · The Journal of Infectious Diseases · 42

PDF

Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study

2023 · Christy A Comeaux, Stephan Bart, et al. · The Journal of Infectious Diseases · 24

PDF

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

2024 · Gerd R Burmester, Jacques-Eric Gottenberg, et al. · Annals of the Rheumatic Diseases · 21

PDF

Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

2025 · Xavier Mariette, Sven Borchmann, et al. · RMD Open · 13

PDF

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study

2024 · Maya H Buch, Daniel Aletaha, et al. · RMD Open · 9

PDF

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months

2024 · Joanne M Langley, Terry M Nolan, et al. · Open Forum Infectious Diseases · 8

PDF

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate

2024 · Maya H Buch, David Walker, et al. · Rheumatology · 5

Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease

2017 · Christophe Hézode, Piero L. Almasio, et al. · Liver International · 5

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

2024 · Roy van Heesbeen, Arangassery Rosemary Bastian, et al. · Vaccine · 4

Pos0051 an Update on the Integrated Safety Analysis of Filgotinib in Patients With Moderate to Severe Active Rheumatoid Arthritis Over a Median of 4.3 Years

2024 · K.L. Winthrop, D. Aletaha, et al. · Annals of the Rheumatic Diseases · 1

Pos0658 Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results From a Post Hoc Analysis of the Finch 4 Study

2024 · M. Buch, P. Verschueren, et al. · Annals of the Rheumatic Diseases · 1

Pos0853 Efficacy of Filgotinib (fil) in Patients (pts) With Rheumatoid Arthritis (ra): Week (w) 156 Results From a Long-term Extension (lte) Study

2023 · M.H. Buch, D. Aletaha, et al. · Annals of the Rheumatic Diseases · 1

PDF

P115 Long-term efficacy of filgotinib monotherapy and combination therapy: interim results from a post hoc analysis of the FINCH 4 study

2025 · Maya Buch, Patrick Verschueren, et al. · Rheumatology

PDF

OA12 An update on the integrated safety analysis of filgotinib in patients with moderate to severe active rheumatoid arthritis over a median of 4.3 years

2025 · Kevin L Winthrop, Daniel Aletaha, et al. · Rheumatology

PDF

Efficacité à long terme du filgotinib en monothérapie et en association : résultats intermédiaires d’une analyse post hoc de l’étude FINCH 4

2024 · G. Mouterde, M.H. Buch, et al. · Revue du Rhumatisme

Mise à jour de l’analyse intégrée de la tolérance du Filgotinib (FIL) chez les patients atteints de polyarthrite rhumatoïde (PR) active modérée à sévère recevant un traitement sur une période médiane de 4,3 ans

2024 · J.E. Gottenberg, D. Aletaha, et al. · Revue du Rhumatisme

P117 Efficacy of filgotinib in patients with rheumatoid arthritis: Week 156 results from a long-term extension study

2024 · Maya H Buch, Daniel Aletaha, et al. · Rheumatology

Efficacité du filgotinib chez des patients atteints de polyarthrite rhumatoïde : résultats à la Semaine 156 d’une étude d’extension long terme

2023 · J.E. Gottenberg, M.H. Buch, et al. · Revue du Rhumatisme

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years

2019 · Christy Comeaux, Arangassery Rosemary Bastian, et al. · Open Forum Infectious Diseases

PDF

Works count: 21

Citation count: 299

H-index: 8

I10-index: 6